A federal lawsuit filed in June 2026 is shining a harsh spotlight on one of the most dangerous medical device failures of the decade: contaminated Olympus duodenoscopes that allegedly cannot be adequately cleaned or disinfected, even when hospital staff follow the manufacturer’s own reprocessing instructions. The plaintiff in this case underwent an Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure in June 2023, contracted Vancomycin-Resistant Enterococcus (VRE), and ultimately died from septic shock and multi-organ failure. The Olympus duodenoscope infection lawsuit now making its way through federal court is not an isolated incident — it is the latest chapter in a years-long regulatory and litigation crisis that has claimed lives, prompted multiple FDA recalls, and left thousands of ERCP patients wondering whether the scope used in their procedure put them at risk.
What Is the Olympus Duodenoscope and Why Is It Dangerous?
Duodenoscopes are specialized, flexible endoscopes threaded through the mouth to reach the small intestine. They are essential for ERCP procedures, which diagnose and treat conditions affecting the bile ducts, pancreas, and gallbladder. The Olympus TJF-Q190V is among the most widely used models in U.S. hospitals. The device features a complex, elevator mechanism at its tip — a small moveable part that guides surgical tools during the procedure. This elevator, and the multiple narrow internal channels surrounding it, creates microscopic crevices that standard cleaning brushes and chemical disinfectants cannot reliably penetrate.
Post-market surveillance data cited in the June 2026 complaint found contamination in a significant percentage of reprocessed endoscopes — even units that had been cleaned strictly according to Olympus’s own published instructions. According to the CDC’s guidance on healthcare-associated outbreaks linked to duodenoscopes, these devices have been associated with clusters of multi-drug-resistant organism infections across U.S. hospitals. When bacteria like VRE survive inside the scope’s channels, the next patient who undergoes an ERCP procedure is directly inoculated with drug-resistant pathogens through their bile duct — one of the fastest routes to bloodstream infection and sepsis.
The June 2026 Federal Lawsuit: Key Allegations Against Olympus
The complaint filed in June 2026 centers on two primary legal theories: strict liability design defect and failure to warn. Under the strict liability design defect claim, plaintiffs argue the Olympus TJF-Q190V was unreasonably dangerous because its multi-channel, elevator-assisted architecture made thorough reprocessing impossible — not due to user error, but due to the device’s fundamental engineering. The failure-to-warn claim alleges that Olympus knew, or should have known, that its reprocessing instructions were inadequate to eliminate bacterial contamination at the levels required for patient safety, yet failed to communicate that risk clearly to hospitals, physicians, and patients.
These are precisely the liability theories that courts have found most persuasive in medical device mass torts. As Cornell Law School’s Legal Information Institute explains, strict products liability does not require proof of negligence — a plaintiff need only show the product was defective and the defect caused injury. In the context of an Olympus duodenoscope infection lawsuit, the defect is baked into the design itself: a device that cannot be made safe through any reasonable cleaning protocol is a defective device, full stop.
FDA Regulatory History: Recalls That Build the Case
One of the most powerful elements of any products liability case is a documented history of regulatory action. In the Olympus duodenoscope infection lawsuit context, that history is damning. The FDA issued a Class II recall for the Olympus TJF duodenoscope in June 2025 due to contamination risk associated with inadequate reprocessing. Less than a year later, in March 2026, the FDA issued another Class II recall — this time targeting the Olympus OER-Pro reprocessor, the very machine designed to automate the cleaning of these scopes.
Two recalls within a twelve-month window for both the device and its dedicated cleaning system signal systemic failure, not isolated manufacturing error. For plaintiffs’ attorneys and juries alike, these regulatory actions serve as powerful corroborating evidence that Olympus had notice of the contamination problem and failed to correct it in time to protect patients. The FDA’s own recall database documents each of these actions, and plaintiffs in the June 2026 lawsuit have cited both recalls prominently in their complaint to establish prior notice — a critical element of failure-to-warn and punitive damages arguments.
Damages Framework: How Much Is an Olympus Duodenoscope Infection Lawsuit Worth?
Valuing an Olympus duodenoscope infection lawsuit requires a careful analysis of the severity of the infection, the speed of diagnosis and treatment, the degree of permanent harm, and — in the most devastating cases — whether the patient survived. The table below summarizes the general damages framework based on sepsis severity and case type.
| Case Type | Injury Severity | Estimated Settlement/Verdict Range | Key Damages Factors |
|---|---|---|---|
| Duodenoscope infection — full recovery | Moderate (hospitalization, IV antibiotics) | $250,000 – $750,000 | Medical bills, lost wages, pain and suffering |
| Duodenoscope infection — serious complications | Severe (ICU, prolonged treatment, partial organ damage) | $750,000 – $2,500,000 | Long-term care, permanent impairment, emotional distress |
| Sepsis with delay in diagnosis | Severe to critical | $1,800,000 – $5,000,000+ | Delay-in-diagnosis liability added to device defect claim |
| Septic shock / multi-organ failure (survived) | Catastrophic | $3,000,000 – $7,500,000+ | Permanent disability, ongoing medical needs, loss of earning capacity |
| Wrongful death (septic shock) | Fatal | $2,000,000 – $10,000,000+ | Loss of consortium, funeral costs, survivor economic loss |
For families who have lost a loved one to a duodenoscope-related infection, a wrongful death calculator can help survivors begin to understand the economic and non-economic losses that form the foundation of a wrongful death claim. These figures are consistent with reported sepsis litigation settlements ranging from $1.8 million to $5 million or more in device defect cases, with outlier jury verdicts reaching well above $10 million when punitive damages are awarded.
MDL Formation, Bellwether Trials, and Settlement Trajectory
Given the volume of patients who have undergone ERCP procedures with Olympus TJF-series duodenoscopes — and the number of reported post-procedure infections documented in post-market surveillance data — the Olympus duodenoscope infection lawsuit filed in June 2026 is unlikely to remain a standalone case for long. Legal observers widely anticipate that a Multi-District Litigation (MDL) consolidation will be sought, mirroring the structure used in earlier duodenoscope litigation involving other manufacturers. Federal MDL procedures, as described by the United States Courts, allow related cases from across the country to be consolidated before a single judge for coordinated pretrial proceedings, including document discovery, expert depositions, and bellwether trial selection.
Bellwether trials — a small number of representative cases tried to verdict before the broader MDL resolves — carry enormous strategic weight. If plaintiffs win early bellwether verdicts on the design defect and failure-to-warn theories, Olympus faces massive settlement pressure to resolve thousands of remaining claims before additional verdicts are rendered. Conversely, a defense verdict in a bellwether trial can dramatically reduce the settlement value of the entire MDL. Given the dual FDA recalls, the contamination data in post-market surveillance, and the documented fatality alleged in the June 2026 complaint, the bellwether risk here appears to favor plaintiffs significantly. The combination of a sympathetic plaintiff who died from septic shock, a device with known cleaning limitations, and two regulatory recalls in under twelve months creates a liability profile that is difficult for any defense team to neutralize before a jury.
Who May Be Eligible to File an Olympus Duodenoscope Infection Lawsuit?
If you or a family member underwent an ERCP procedure using an Olympus duodenoscope — particularly an Olympus TJF-series scope — and subsequently developed any of the following conditions, you may have grounds to pursue an Olympus duodenoscope infection lawsuit: a drug-resistant bacterial infection (including VRE, CRE, or MRSA) diagnosed within weeks of the procedure; sepsis or septic shock requiring hospitalization; multi-organ failure; or wrongful death attributed to a post-ERCP infection. As Nolo’s products liability FAQ explains, patients harmed by defective medical devices generally have the right to pursue compensation from the manufacturer without needing to prove negligence — only that the product was defective and caused their injury.
Statute of limitations deadlines vary by state and typically run from the date of injury or the date the patient discovered — or reasonably should have discovered — that the device caused their harm. Given the recent FDA recalls and the June 2026 filing activity, individuals who experienced post-ERCP infections in 2023, 2024, or 2025 should consult with a qualified personal injury attorney as soon as possible to evaluate whether their claims remain timely.
Frequently Asked Questions About the Olympus Duodenoscope Infection Lawsuit
What is the Olympus duodenoscope infection lawsuit about?
The Olympus duodenoscope infection lawsuit filed in June 2026 alleges that the Olympus TJF-Q190V duodenoscope was defectively designed with complex multi-channel components that cannot be adequately cleaned or disinfected, even when hospital staff follow the manufacturer’s own reprocessing instructions. The plaintiff developed VRE (Vancomycin-Resistant Enterococcus) following an ERCP procedure in June 2023 and died from septic shock and multi-organ failure. The lawsuit asserts strict liability design defect and failure-to-warn claims against Olympus Medical Systems, supported by two FDA recalls issued in June 2025 and March 2026.
What FDA recalls support the Olympus duodenoscope infection claims?
Two significant FDA Class II recalls directly support pending Olympus duodenoscope infection lawsuit claims. In June 2025, the FDA issued a Class II recall for the Olympus TJF duodenoscope due to contamination risk from inadequate reprocessing. In March 2026, the FDA issued a second Class II recall for the Olympus OER-Pro reprocessor — the automated cleaning system designed to decontaminate the scopes. Together, these recalls establish that both the device itself and its dedicated cleaning system were identified as defective by federal regulators within a twelve-month period, providing strong notice evidence for failure-to-warn claims.
How much compensation can victims recover in an Olympus duodenoscope lawsuit?
Compensation in an Olympus duodenoscope infection lawsuit depends on the severity of the infection and its consequences. Cases involving full recovery may settle in the range of $250,000 to $750,000. Cases involving severe sepsis, ICU hospitalization, and partial organ damage may reach $750,000 to $2.5 million. Cases involving septic shock, catastrophic permanent injury, or wrongful death are estimated to range from $2 million to $10 million or more, particularly when punitive damages are sought based on Olympus’s prior knowledge of contamination risks documented in post-market surveillance data and FDA regulatory actions.
Will Olympus duodenoscope cases be consolidated into an MDL?
Legal observers widely anticipate that an MDL (Multi-District Litigation) will be formed to consolidate Olympus duodenoscope infection lawsuits filed across the country. This mirrors the structure used in prior duodenoscope litigation involving other manufacturers. MDL consolidation allows for coordinated discovery, expert witness proceedings, and bellwether trials — a small number of representative cases tried to jury verdict. Given the dual FDA recalls, documented post-market contamination data, and the June 2026 complaint filing, plaintiffs appear to hold a strong bellwether position, which typically accelerates global settlement negotiations in medical device mass torts.
Who is eligible to file an Olympus duodenoscope infection lawsuit in 2026?
Individuals who underwent an ERCP procedure using an Olympus TJF-series duodenoscope and subsequently developed a drug-resistant bacterial infection (including VRE, CRE, or MRSA), sepsis, septic shock, multi-organ failure, or who lost a family member to a post-ERCP infection may be eligible to file an Olympus duodenoscope infection lawsuit. Eligibility is subject to state-specific statutes of limitations, which typically run from the date of injury or the date the patient reasonably discovered the device caused their harm. Patients who experienced post-ERCP infections in 2023, 2024, or 2025 should seek a legal evaluation promptly to protect their rights.
This article is provided for general informational purposes only and does not constitute legal advice; individuals with potential claims should consult a licensed personal injury attorney in their jurisdiction.
Related reading: Spinal Cord Injury Settlement Calculator: Calculate Your Paralysis Claim Value By Injury Severity (2026)
Related reading: House Passes TBI Reauthorization: What The New Chronic Condition Study Means For Brain Injury Litigation
James Mitchell is a personal injury legal researcher with over a decade of experience analyzing settlement data and compensation trends across the United States. He has studied thousands of personal injury cases to help injury victims understand their legal rights and the potential value of their claims. James is not an attorney and the information he provides is for
educational purposes only.